Harvard spinout Emulate will use the cash to further develop its organ-on-a-chip technology, having now raised nearly $225m in total.
Emulate, a US-based biotechnology developer spun out of Harvard University, raised $82m in a series E round led Northpond Ventures on Tuesday.
Perceptive Advisors also contributed funding, bringing the company’s total capital to almost $225m.
Emulate is developing in vitro on-a-chip models of human organs that replicate their function, in order to aid research in human response to drugs.
In addition to potentially accelerating the drug discovery process, the technology is set to benefit from anticipated changes…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
